Nalbuphine Pretreatment Improves Myocardial Cell Viability Induced by H/R Through TLR4/NLRP3-Mediated Pyroptosis

Yanna Chang,Hai Xie,Zhijie Gao,Huimin Liu
DOI: https://doi.org/10.1007/s40995-022-01290-w
2022-04-27
Abstract:Myocardial ischemic–reperfusion injury (MIRI) has been the nonnegligible obstacle for the treatment of myocardial infarction that is the dominating cause of morbidity and mortality in cardiovascular diseases around the world. To explore the potential therapeutic drugs and the underlying molecular mechanisms of the MIRI, hypoxia/reoxygenation (H/R) was used to treat H9c2 cardiomyocyte cells to simulate MIRI. The cell viability of H9c2 cardiomyocyte cells was a dose-dependent reduction with nalbuphine, and the maximum non-toxic concentration of nalbuphine was 200 μM. H/R treatment significantly decreased cell viability and increased the rate of pyroptosis and pyroptosis-related proteins levels of H9c2 cardiomyocyte cells, which was prominently reversed with 200 μM nalbuphine pretreatment. Moreover, TLR4 overexpression prominently reduced the cell viability and enhanced the rate of pyroptosis and pyroptosis-related proteins levels of H9c2 cardiomyocyte cells based on the pretreatment of nalbuphine. Therefore, nalbuphine pretreatment improved myocardial cell viability induced by H/R through TLR4/NLRP3-mediated pyroptosis.
What problem does this paper attempt to address?